Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves’ Ophthalmopathy through the Regulation of FoxO3a Signaling
Graves’ ophthalmopathy (GO), which is characterized by orbital tissue inflammation, expansion, and fibrosis, is the ocular manifestation in 25% to 50% of patients with Graves’ disease. As the pathology of GO is driven by autoimmune inflammation, many proinflammatory cytokines/chemokines, including T...
Saved in:
| Main Authors: | Yi-Hsuan Wei, Shu-Lang Liao, Chia-Chun Wang, Sen-Hsu Wang, Wan-Chun Tang, Chang-Hao Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2021/8888913 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cyr61 in kidney injury and inflammation: From biomarker to therapeutic target
by: Yu-Jui Chang, et al.
Published: (2025-08-01) -
CYR61 delivery promotes angiogenesis during bone fracture repair
by: Annemarie Lang, et al.
Published: (2025-04-01) -
RAGE and HMGB1 Expression in Orbital Tissue Microenvironment in Graves’ Ophthalmopathy
by: Dominika Łacheta, et al.
Published: (2021-01-01) -
Cyr61 Promotes Inflammation of a Gouty Arthritis Model in Rats
by: Mi Zhou, et al.
Published: (2020-01-01) -
CYR61 as a Potential Biomarker and Target in Cancer Prognosis and Therapies
by: Andrew J. Schenker, et al.
Published: (2025-05-01)